Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Patient Services
U.S. Product List
Research & Development
Our Pipeline
Therapeutic Areas
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
In Their Shoes
The Key Elements at the Heart of Our Innovation
Partnerships as Catalysts for Innovation
Caring
Medicine for the World
Heritage
Keys to Aging Gracefully
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Commitment to Community
Our Environment
Culture of Compliance
Federal
CPSIA
State
Open Payments and Transparency Reporting
Diversity and Inclusion
Independent Medical Education Grants
Takeda Pricing Philosophy
Lobbying & Political Contributions
Patient Assistance
ADHD Medicines Misuse
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
NATPARA Updates
COVID-19 Updates
News Releases
Enter
All
Last 12 months
2017
2016
2015
2014
2013
2012
2009
2008
2007
2005
2004
2003
2002
2000
April 2020
April 23, 2020
4/23/2020
ProThera Biologics and Takeda Enter Global Licensing Agreement
April 16, 2020
4/16/2020
USBU COVID-19 Supply Statement
March 2020
March 25, 2020
3/25/2020
Supporting Our Communities During the COVID-19 Outbreak
March 12, 2020
3/12/2020
Supporting Our Healthcare Providers During COVID-19
March 6, 2020
3/6/2020
Update on US Recall of Two Lots of VONVENDI® [von Willebrand factor (recombinant)]
February 2020
February 25, 2020
2/25/2020
Takeda Issues US Recall of Two Lots of VONVENDI
February 10, 2020
2/10/2020
Takeda to Present Research Advances in Rare Lysosomal Storage Disorders at 16th Annual WORLDSymposium™ 2020
December 2019
December 20, 2019
12/20/2019
Takeda Receives Complete Response Letter from U.S. FDA for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
1
2
3
4
5
TOP
